{"id":1151,"date":"2021-06-06T20:58:12","date_gmt":"2021-06-06T18:58:12","guid":{"rendered":"https:\/\/imi-pharma.com\/?page_id=1151"},"modified":"2021-06-15T11:11:24","modified_gmt":"2021-06-15T09:11:24","slug":"metaboliket","status":"publish","type":"page","link":"https:\/\/imi-pharma.com\/english\/?page_id=1151","title":{"rendered":"Metabolik\u00ebt"},"content":{"rendered":"

[vc_row][vc_column width=”1\/2″][vc_custom_heading text=”Diabeti”][vc_column_text]<\/p>\n

Diabeti \u00ebsht\u00eb nj\u00eb shkak kryesor i vdekjeve n\u00eb vendet e zhvilluara, dhe problemi po p\u00ebrkeq\u00ebsohet.<\/p>\n

Diabeti lind kur trupi nuk mund t\u00eb prodhoj\u00eb mjaftuesh\u00ebm insulin\u00eb (diabeti tip 1) ose kur trupi prodhon insulin\u00eb por nuk mund ta p\u00ebrdor\u00eb at\u00eb si\u00e7 duhet (diabeti tip 2). T\u00eb dy kushtet jan\u00eb serioze dhe k\u00ebrkojn\u00eb monitorim dhe kontroll t\u00eb kujdessh\u00ebm.<\/p>\n

Diabeti \u00ebsht\u00eb nj\u00eb k\u00ebrc\u00ebnim n\u00eb rritje global p\u00ebr sh\u00ebndetin dhe shkaku i 7-t\u00eb m\u00eb i madh i vdekjeve n\u00eb njer\u00ebz, me rreth 425 milion njer\u00ebz n\u00eb t\u00eb gjith\u00eb bot\u00ebn q\u00eb vuajn\u00eb nga diabeti. Diabeti tani \u00ebsht\u00eb shkaku i kat\u00ebrt kryesor i vdekjeve n\u00eb shumic\u00ebn e vendeve t\u00eb zhvilluara. \u00c7do vit, m\u00eb shum\u00eb se tre milion vdekje n\u00eb t\u00eb gjith\u00eb bot\u00ebn jan\u00eb p\u00ebr shkak t\u00eb shkaqeve q\u00eb lidhen me diabetin.<\/p>\n

Partneriteti IMIPHARMA me MERCK \u00ebsht\u00eb pozicionuar s\u00eb bashku n\u00eb ofrimin e zgjidhjeve p\u00ebr shqet\u00ebsimet q\u00eb rrisin kujdesin sh\u00ebndet\u00ebsor<\/p>\n

N\u00eb Merck, ne kemi qen\u00eb t\u00eb p\u00ebrkushtuar n\u00eb luft\u00ebn kund\u00ebr diabetit t\u00eb tipit 2 p\u00ebr m\u00eb shum\u00eb se 60 vjet. P\u00ebrmes p\u00ebrvoj\u00ebs son\u00eb klinike dhe bashk\u00ebpunimeve inovative, ne jemi duke luftuar rritjen e k\u00ebsaj s\u00ebmundjeje dhe duke ndihmuar profesionist\u00ebt e kujdesit sh\u00ebndet\u00ebsor t\u00eb menaxhojn\u00eb dhe parandalojn\u00eb at\u00eb. Ne jemi angazhuar n\u00eb luft\u00ebn kund\u00ebr diabetit t\u00eb tipit 2 p\u00ebr m\u00eb shum\u00eb se 60 vjet me portofolin ton\u00eb t\u00eb larmish\u00ebm Glucophage\u00ae<\/p>\n

[\/vc_column_text][\/vc_column][vc_column width=”1\/2″][vc_custom_heading text=”Diabetes”][vc_column_text]<\/p>\n

Diabetes is a major cause of death\u00a0 in developed countries, and the problem is getting worse.<\/p>\n

Diabetes arises when the body cannot produce enough insulin (type 1 diabetes) or when the body produces insulin but cannot use it properly (type 2 diabetes). Both conditions are serious and require careful monitoring and control.<\/p>\n

Diabetes is a growing global health threat and the 7th biggest cause of death in humans, with an estimated 425\u00a0 million\u00a0 people worldwide suffering from diabetes. Diabetes is now the fourth leading cause of death in most developed countries. Each year, more than three million deaths worldwide are due to diabetes-related causes.<\/p>\n

IMIPHARMA partnering with MERCK is positioned along side on providing solutions for that health care raising concern<\/p>\n

At Merck, we\u2019ve been committed to the fight against type 2 diabetes for more than 60 years. Through our clinical experience and innovative collaborations, we are fighting the rise of this disease and helping healthcare professionals both manage and prevent it. We\u2019ve been committed to the fight against type 2 diabetes for more than 60 years with our diverse portfolio Glucophage\u00ae<\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_separator][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/2″][vc_custom_heading text=”Tiroide”][vc_column_text]<\/p>\n

Miliona njer\u00ebz vuajn\u00eb nga s\u00ebmundjet tiroide. Sidoqoft\u00eb, kjo s\u00ebmundje mbetet ende e padiagnostikuar n\u00eb mesin e popullat\u00ebs. IMIPHARMA, p\u00ebrmes gam\u00ebs s\u00eb produkteve t\u00eb Merck, ofron zgjidhje me kosto efektive p\u00ebr t\u00eb adresuar k\u00ebt\u00eb \u00e7\u00ebshtje m\u00eb t\u00eb madhe sh\u00ebndet\u00ebsore globale<\/p>\n

[\/vc_column_text][\/vc_column][vc_column width=”1\/2″][vc_custom_heading text=”Thyroid”][vc_column_text]<\/p>\n

Millions of people are suffering from thyroid diseases. However, this disease still remains undiagnosed among the population. IMIPHARMA, through Merck\u2019s product range, offers cost-effective\u00a0 solutions to address this biggest global health issue<\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_separator][\/vc_column][\/vc_row][vc_row][vc_column][home_blog style=”grid” posts_per_page=”25″ dynamic_from_where=”cat” dynamic_cat=”17″][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column width=”1\/2″][vc_custom_heading text=”Diabeti”][vc_column_text] Diabeti \u00ebsht\u00eb nj\u00eb shkak kryesor i vdekjeve n\u00eb vendet e zhvilluara, dhe problemi po p\u00ebrkeq\u00ebsohet. Diabeti lind kur trupi nuk mund t\u00eb prodhoj\u00eb mjaftuesh\u00ebm insulin\u00eb (diabeti tip 1) ose kur trupi prodhon insulin\u00eb por nuk mund ta p\u00ebrdor\u00eb at\u00eb si\u00e7 duhet (diabeti tip 2). T\u00eb dy kushtet jan\u00eb serioze dhe k\u00ebrkojn\u00eb monitorim […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1151","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/imi-pharma.com\/english\/index.php?rest_route=\/wp\/v2\/pages\/1151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/imi-pharma.com\/english\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/imi-pharma.com\/english\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/imi-pharma.com\/english\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/imi-pharma.com\/english\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1151"}],"version-history":[{"count":4,"href":"https:\/\/imi-pharma.com\/english\/index.php?rest_route=\/wp\/v2\/pages\/1151\/revisions"}],"predecessor-version":[{"id":1690,"href":"https:\/\/imi-pharma.com\/english\/index.php?rest_route=\/wp\/v2\/pages\/1151\/revisions\/1690"}],"wp:attachment":[{"href":"https:\/\/imi-pharma.com\/english\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}